Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Inclusion criteria

• Diagnosis of neovascular glaucoma
• The patients having IOP > 21 mmHg, having the indication for trabeculectomy
• The patients' age of at least 18-year-old
• The patients having visual potential at least hand motion.
• Present of NVI or NVA.
• Willing and able to provide informed consent to participate in the study
• Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

Exclusion criteria

• One eye patient
• Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
• Cannot obtain endothelial cell count.
• History of bevacizumab or fluorescence dye allergy.
• Active infectious ocular disease including endophthalmitis and corneal ulcer
• History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
• Has or planning to be pregnant or breastfeeding